Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Galderma Group AGXSWX:GALD -2.71%15 3-Year EBITDA Growth Rate is 16.00% as of Jun. 2026, which is 13% below its 10-year median of 18.40. GuruFocus rates XSWX:GALD with a GF Score™ of 15/100. The stock has 3 warning signs investors should review. Among 813 Drug Manufacturers companies, Galderma Group AG ranks better than 62.36% on this metric.
During the past 12 months, Galderma Group AG's average EBITDA Per Share Growth Rate was 33.60% per year.
During the past 3 years, the average EBITDA Per Share Growth Rate was 16.00% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
During the past 5 years, the highest 3-Year average EBITDA Per Share Growth Rate of Galderma Group AG was 20.80% per year. The lowest was 16.00% per year. And the median was 18.40% per year.
Galderma Group AG (XSWX:GALD) 3-Year EBITDA Growth Rate Explanation
EBITDA per Share is the amount of Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) per outstanding share of the company's stock.
Earnings Before Interest, Taxes, Depreciation, and Amortization (EBITDA) is what the company earns before it expenses interest, taxes, depreciation and amortization.
Galderma Group AG 3-Year EBITDA Growth Rate Related Terms
XSWX:GALD vs ZTS, UTHR, VTRS: 3-Year EBITDA Growth Rate Comparison
For the Drug Manufacturers - Specialty & Generic subindustry, Galderma Group AG's 3-Year EBITDA Growth Rate, along with its competitors' market caps and 3-Year EBITDA Growth Rate data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Galderma Group AG 3-Year EBITDA Growth Rate vs Drug Manufacturers Industry
For the Drug Manufacturers industry and Healthcare sector, Galderma Group AG's 3-Year EBITDA Growth Rate distribution charts can be found below:
* The bar in red indicates where Galderma Group AG's 3-Year EBITDA Growth Rate falls into.
Galderma Group AG 3-Year EBITDA Growth Rate Calculation
This is the 3-year average growth rate of EBITDA per Share. The growth rate is calculated using exponential compounding based on the latest four year annual data.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the average EBITDA per share growth rate.
What does a 3-Year EBITDA Growth Rate of 16.00% mean?
Galderma Group AG (XSWX:GALD) has a 3-Year EBITDA Growth Rate of 16.00% as of Jun. 2026. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Galderma Group AG and its competitors. This is 13% below median its historical median of 18.40. Over the past decade, Galderma Group AG's 3-Year EBITDA Growth Rate has ranged from 16.00 to 20.80. According to the industry distribution chart, Galderma Group AG ranks #306 out of 813 companies in the Drug Manufacturers industry, placing it in the top 37.6%.
Is Galderma Group AG's 3-Year EBITDA Growth Rate too high?
Galderma Group AG's current 3-Year EBITDA Growth Rate of 16.00% is 13% below median its 10-year median of 18.40. Over the past 10 years, this metric has ranged from a low of 16.00 to a high of 20.80. The Drug Manufacturers industry median 3-Year EBITDA Growth Rate is 8.90. Galderma Group AG's value of 16.00% is 79.8% above this industry median. Based on the distribution chart, Galderma Group AG ranks #306 out of 813 companies in the Drug Manufacturers industry, which is above the industry midpoint. Overall, Galderma Group AG has a GF Score™ of 15/100, reflecting its overall financial health beyond just this single metric.
How does Galderma Group AG's 3-Year EBITDA Growth Rate compare to ZTS and UTHR?
According to the Drug Manufacturers industry distribution chart, Galderma Group AG ranks #306 out of 813 companies for 3-Year EBITDA Growth Rate. This puts Galderma Group AG in the upper half of its industry. The industry median 3-Year EBITDA Growth Rate is 8.90. Galderma Group AG's value of 16.00% is 79.8% above this benchmark. Historically, Galderma Group AG's own 3-Year EBITDA Growth Rate has ranged from 16.00 to 20.80 over the past decade. While the company's 10-year median is 18.40 vs. the industry median of 8.90, Galderma Group AG has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year EBITDA Growth Rate for a Drug Manufacturers company?
The median 3-Year EBITDA Growth Rate among Drug Manufacturers companies is 8.90, based on 813 companies in the industry. Companies in the top quartile (top 25%) have a 3-Year EBITDA Growth Rate significantly above this median, while those in the bottom quartile fall well below. However, 3-Year EBITDA Growth Rate should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Galderma Group AG's current 3-Year EBITDA Growth Rate of 16.00% is 79.8% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year EBITDA Growth Rate mean?
A high 3-Year EBITDA Growth Rate can signal that a stock is expensive relative to its fundamentals. 3-Year EBITDA Growth Rate is the 3-year average growth rate of EBITDA per share. View historical data for Galderma Group AG and its competitors. For the Drug Manufacturers industry, the median 3-Year EBITDA Growth Rate is 8.90 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Galderma Group AG's current 3-Year EBITDA Growth Rate is 16.00%, which is 13% below median its own 10-year median of 18.40. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Galderma Group AG stock overvalued right now?
Galderma Group AG (XSWX:GALD) has a current 3-Year EBITDA Growth Rate of 16.00%. The current 3-Year EBITDA Growth Rate is 16.00%, which is 13% below median its 10-year median of 18.40 and 79.8% above the Drug Manufacturers industry median of 8.90. Galderma Group AG's overall GF Score™ is 15/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year EBITDA Growth Rate calculated?
3-Year EBITDA Growth Rate is calculated from a company's financial statements. For Galderma Group AG (XSWX:GALD), the current 3-Year EBITDA Growth Rate is 16.00% as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Galderma was formed in 1981 as a joint venture between Nestle and L'Oreal. It subsequently became a subsidiary of Nestle, called Nestle Skin Health, before being carved out and launched as a stand-alone company in 2019, acquired by a consortium led by Sweden-based EQT fund. The company went public in March 2024 and is listed on the SIX Swiss exchange. Galderma's science-based portfolio spans multiple dermatology categories, including injectable aesthetics, dermatological skincare, and therapeutic dermatology. It derives around 40% of net sales from the US and employs more than 7,500 people.
15GF Score
Get the complete analysis for XSWX:GALD
3-Year EBITDA Growth Rate is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
XSWX:GALD has been successfully added to your 
